Blow for Eli Lilly as research institute deems diabetes candidate no better than competition

Eli Lilly’s type 2 diabetes candidate, tirzepatide, is no better than other diabetes drugs on the market, including Novo Nordisk’s blockbuster Ozempic, according to the Institute for Clinical and Economic Review.
Photo: Mike Segar/Reuters/Ritzau Scanpix
Photo: Mike Segar/Reuters/Ritzau Scanpix
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

Eli Lilly’s tirzepatide – presumably the biggest competition for Novo Nordisk’s new generation of diabetes drugs – is not more effective than other type 2 diabetes treatments on the market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading